Q3 2025 Neurocrine Biosciences Inc Earnings Call Transcript
Key Points
- Neurocrine Biosciences Inc (NBIX) reported a strong third quarter with $790 million in net product sales, reflecting a 28% year-over-year growth.
- The company achieved record new patient starts and total prescriptions for INGREZZA, driven by sales force expansion and improved patient access.
- CRENESSITY's launch has been successful, with net sales growing from $53 million in Q2 to $98 million in Q3, and 80% of prescriptions being reimbursed.
- Neurocrine Biosciences Inc (NBIX) is on track to meet its R&D productivity goals, including four new Phase I study initiations and two new Phase II initiations.
- The company has a strong financial position with over $2.1 billion in cash, supporting continued investment in its internal pipeline and future growth.
- The company faces potential impacts from the Inflation Reduction Act, which could affect INGREZZA's market dynamics and pricing strategies.
- There is an ongoing DOJ investigation into the sales, marketing, and promotion of INGREZZA, which could pose legal and reputational risks.
- The expansion of the sales force for both INGREZZA and CRENESSITY will result in an SG&A expense increase of around $150 million in 2026.
- Despite strong sales, only about 10% of the tardive dyskinesia population is currently being treated with the VMAT2 Inhibitor, indicating a significant untapped market.
- The company received a warning letter regarding DTC advertisements, which may require adjustments to its marketing strategies.
Good day, everyone, and welcome to today's Neurocrine Biosciences third-quarter 2025 results call. (Operator Instructions) Please note, this call is being recorded. I will be standing by if you should need any assistance.
It is now my pleasure to turn the conference over to Vice President of Investor Relations, Todd Tushla.
Hi, everybody, and a very pleasant good afternoon to you wherever you may be. Welcome to Neurocrine Biosciences third-quarter 2025 earnings call. I'm joined today by Kyle Gano, Chief Executive Officer; Matt Abernethy, Chief Financial Officer; Eric Benevich, Chief Commercial Officer; and Sanjay Keswani, Chief Medical Officer.
During our call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. After prepared remarks and as is our standard practice, we will try to address all your
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
